Program
HRS-3095
A development code. Also written as “HRS-3095 Tablet”.
Its studies are mostly in Chronic Urticaria, led by Jiangsu HengRui Medicine.
Furthest: phase 2, since May 22, 20263 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 32 open or running | phase 2since May 22, 2026 | Nov 13, 2025 | Dec 2026phase 2 · NCT07613866 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-3095
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 13, 2025First study: phase 1 study in Chronic UrticariaFirst studyNCT07230418 · 82 enrolled · China
- May 22, 2026Phase 2 study in Chronic UrticariaPhase 2 reachedNCT07613866 · 190 planned · China
- Jun 22, 2026Early phase 1 study in Chronic UrticariaNCT07686484 · 36 enrolled · Australia
Ahead
- Dec 2026Primary completion: phase 2 study in Chronic UrticariaNCT07613866
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07686484Chronic Urticaria · Australia | Early 1 | Active, not recruiting | Oct 16, 2026 | 36 |
| NCT07613866Chronic Urticaria · China | 2 | Not yet recruiting | Dec 2026 | 190 |
| NCT07230418Chronic Urticaria · China | 1 | Completed | Apr 19, 2026 | 82 |
How it is read
Names in the registry
- “HRS-3095”, 3 entries
- “HRS-3095 Tablet”, 2 entries
Codes read as this program: HRS3095.
Conditions, from the studies’ own filings
- Chronic Urticaria, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.